350. Surveillance for Carbapenem-Resistant Pseudomonas aeruginosa at Five U.S. Sites – 2015
Session: Poster Abstract Session: HAI: Multi Drug Resistant Gram Negatives
Thursday, October 27, 2016
Room: Poster Hall
Background: Pseudomonas aeruginosa causes approximately 51,000 healthcare-associated infections in the U.S. annually. P. aeruginosa can acquire resistance to carbapenems through chromosomal mutations, changes in gene expression, and acquisition of mobile elements harboring resistance genes. We piloted surveillance for carbapenem-resistant P. aeruginosa (CRPA).

Methods: During July-October 2015, laboratory-based surveillance was conducted at sentinel facilities in GA, NM, OR and TN, and at all facilities in Rochester, NY. A case was isolation of P. aeruginosa resistant to imipenem, meropenem or doripenem from a clinical specimen (except rectal, peri-rectal, or nasal swabs); an incident case was the first case occurring in a patient in a 30-day period. Patient medical records were reviewed. The proportion resistant was determined by dividing the number of cases by the number of isolates tested for carbapenem susceptibility. Isolates were screened by PCR for carbapenemase-encoding genes.

Results: During the 4-month period, 384 (9.1%) of 4243 isolates were carbapenem-resistant; the percent resistant ranged from 4.6% (26/560) in OR to 12% (68/566) in GA. We identified 294 incident cases among 274 patients. In NY, there were 8 incident cases per 100,000 population. Patients had a median age of 66 years (range: <1-98); 115 (42.0%) were female; the most common underlying condition was chronic pulmonary disease (98/272; 36%). Specimens were most commonly from respiratory sites (118; 40.1%) or urine (110; 37.4%); 64 (21.8%) were collected after the third hospital day. Only 23 (7.8%) cases were from patients without any identified healthcare risk factors; the most frequent healthcare risk factor was hospitalization in the prior year (208/253; 82.2%). Death occurred in 27/289 (9.3%) cases. Carbapenemase-encoding genes were identified in 2 of 131 (1.5%) isolates tested; both were from NM and carried either blaVIM-2 or blaIMP-18.

Conclusion: These data suggest that the incidence of CRPA might be greater than that of CR-Enterobacteriaceae and CR-Acinetobacter. Isolates with plasmid-mediated carbapenemases were rare. Multiple years of population-based CRPA rate data are needed to understand CRPA burden and the prevalence of carbapenemase-producing CRPA.

Maroya Spalding Walters, PhD1, Sandra Bulens, MPH1, Emily B. Hancock, MS2,3, Erin C. Phipps, DVM, MPH2,3, Daniel Muleta, MD, MPH4, Jacquelyn Mounsey, BSN, RN, CCRP5, Marion Kainer, MBBS, MPH, FSHEA4, Cathleen Concannon, MPH6, Ghinwa Dumyati, MD, FSHEA6, Chris Bower, MPH7,8,9, Jesse T. Jacob, MD10, P. Maureen Cassidy, MPH11, Zintars G. Beldavs, MS11, Uzma Ansari, MS1, Valerie Albrecht, MPH1, Maria S. Karlsson, PhD1, J. Kamile Rasheed, PhD1 and Alexander Kallen, MD, MPH1, (1)Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, (2)University of New Mexico, Albuquerque, NM, (3)New Mexico Emerging Infections Program, Albuquerque, NM, (4)Tennessee Department of Health, Nashville, TN, (5)Vanderbilt University, Nashville, TN, (6)New York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, NY, (7)Georgia Emerging Infections Program, Decatur, GA, (8)Atlanta Veterans Affairs Medical Center, Decatur, GA, (9)Atlanta Research and Education Foundation, Decatur, GA, (10)Emory University School of Medicine, Atlanta, GA, (11)Oregon Health Authority, Portland, OR

Disclosures:

M. Spalding Walters, None

S. Bulens, None

E. B. Hancock, None

E. C. Phipps, None

D. Muleta, None

J. Mounsey, None

M. Kainer, None

C. Concannon, None

G. Dumyati, None

C. Bower, None

J. T. Jacob, None

P. M. Cassidy, None

Z. G. Beldavs, None

U. Ansari, None

V. Albrecht, None

M. S. Karlsson, None

J. K. Rasheed, None

A. Kallen, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.